Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Neurology

Cordis FDA Approval for MYNX CONTROL VENOUS Vas...

Cordis Secured FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device, Expanding Proven MYNX Technology to Mid-Bore Venous Puncture Sites On July 9, 2024, Cordis, a leading company in cardiov...

Jul 11, 2024

kinsunla-for-alzheimer-disease-treatment
A New Dawn in Alzheimer’s Disease Treatment: Eli Lilly’s Donanemab Wins FDA Approval

The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KINSUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanema...

Find More
medtech-news-for-artivion-masimo-icecure
Artivion and Endospan Agreement; Masimo and Cleveland Clinic Collaboration; Academic Medical Center’s Sedation-Free TNE With the EvoEndo Endoscopy System; IceCure’s Next-Gen XSenseTM Cryoablation System FDA Approval; KORU Medical Systems’ Clearance for FreedomEdge® Infusion System; Reflow Medical’s First Patient in Coronary Sirolimus-Eluting Retrievable Scaffold System

Artivion Amended Agreements With Endospan On June 01, 2024, Artivion, Inc. a prominent company in cardiac and vascular surgery specializing in aortic disease, announced that it revised its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer o...

Find More
medtech-news-for-alcon-globus-medical-ricoh-esaote
Alcon’s 510(k) Clearance From the FDA; Globus Medical Received FDA Clearance; UK Pioneers First Skull-Mounted Epilepsy Device for Child; The Initiation of a Significant Clinical Trial of 3d Printed Models; Esaote Unveiled the Cutting-Edge Mylab™E80 @Sirm Ultrasound Device For 2024; Medasense Unveiled a Transformative Partnership With Nihon Kohden Corporation

Alcon's Newest Technological Marvels, Unity VCS, and Unity CS, Achieved 510(k) Clearance From the U.S. FDA, Paving the Way for New Advancements  On June 24, 2024, Alcon, the foremost name in eye care with a mission to help people see brilliantly, revealed that the U.S. Food and Drug Administration (FDA) had...

Find More

More Views & Analysis

evolving-amyotrophic-lateral-sclerosis-treatment-landscape
Unveiling Amyotrophic Lateral Sclerosis (ALS) Treatment Frontiers: Navigating Challenges, Overcoming Setbacks, and Emerging Therapeutic Horizons

DelveInsight forecasts that with the launch of 15+ emerging therapies alongside existing treatments, the ALS treatment market is anticipated to surpass USD 4 billion across the 7MM by 2034. Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. As per ou...

Find More

role-of-infusion-therapy-devices
Infusion Therapy Devices: Revolutionizing Healthcare Delivery

In contemporary healthcare, technological progress has profoundly reshaped how patients are treated. One such innovation that has revolutionized healthcare delivery is the development of infusion therapy devices. These devices have become indispensable tools in administering fluids, medications, and nutrients direc...

Find More

wireless-brain-sensors-in-healthcare
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare

The advancement of technology has ushered in an era where the fusion of biology and electronics is becoming increasingly seamless. One of the most groundbreaking innovations in this domain is wireless brain sensors. These devices promise to revolutionize neuroscience research, enhance healthcare delivery, and impro...

Find More

pharma-news-for-astrazeneca-biogen-altrubio-gsk
AstraZeneca’s Tropion-Lung01 Phase III Trial Positive Outcomes; Biogen’s LEQEMBI South Korea Approval; AltruBio’s $225M Series B Funding; GSK’s Depemokimab Positive Phase III Severe Asthma Results; Roche’s Inavolisib FDA Breakthrough Therapy Designation

The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy The high-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which had previously met the dual primary endpoint o...

Find More

pharma-news-for-amgen-bms-abbvie-eisai
Amgen’s IMDELLTRA FDA Approval; J&J’s Proteologix Acquisition; Bristol Myers Squibb’s BREYANZI FDA Approval; AbbVie and Gilgamesh Pharmaceuticals’ Agreement; Eisai’s LEQEMBI FDA Fast Track Status

IMDELLTRA Receives FDA Approval as the First T-Cell Engager Therapy for Advanced Small Cell Lung Cancer Amgen has reported that the FDA has approved IMDELLTRA™ (tarlatamab-dlle) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following pl...

Find More

pharma-news-for-takeda-ac-immune-eli-lilly-bristol-myers-squibb
Takeda and AC Immune’s Alzheimer’s Deal; Eli Lilly’s Donanemab FDA Review; Bristol Myers Squibb’s Phase III CheckMate -73L Trial Result; Regeneron Pharmaceuticals’ Dupixent sBLA; Excision BioTherapeutics’ EBT-101 Phase I/II Trial Results

Takeda and AC Immune Ink Exclusive Deal for Active Immunotherapy in Alzheimer’s, Focusing on Amyloid Beta Takeda and AC Immune SA have unveiled an exclusive global option and licensing pact concerning AC Immune’s active immunotherapies directed at harmful variants of amyloid beta (Abeta), notably ACI-24.060, int...

Find More

Cell therapies now are often recommended to treat cancer in several ways, out of which CAR T-cell th.....

Find More

Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....

Find More

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....

Find More

An inherited disorder, Von Hippel-Lindau (VHL) syndrome is characterized by the formation of tumors .....

Find More

In the past few years, online buying has become the easiest way to purchase products and services. T.....

Find More

Nestlé and Unilever are multinational corporations established in 1866 and 1930, respectively. The .....

Find More